ProQR Therapeutics BV (PRQR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
ProQR Therapeutics BV stock (PRQR) is currently trading at $1.58. ProQR Therapeutics BV PS ratio (Price-to-Sales) is 9.99. Analyst consensus price target for PRQR is $8.88. WallStSmart rates PRQR as Sell.
- PRQR PE ratio analysis and historical PE chart
- PRQR PS ratio (Price-to-Sales) history and trend
- PRQR intrinsic value — DCF, Graham Number, EPV models
- PRQR stock price prediction 2025 2026 2027 2028 2029 2030
- PRQR fair value vs current price
- PRQR insider transactions and insider buying
- Is PRQR undervalued or overvalued?
- ProQR Therapeutics BV financial analysis — revenue, earnings, cash flow
- PRQR Piotroski F-Score and Altman Z-Score
- PRQR analyst price target and Smart Rating
ProQR Therapeutics BV
📊 No data available
Try selecting a different time range
Smart Analysis
ProQR Therapeutics BV (PRQR) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
ProQR Therapeutics BV (PRQR) Key Strengths (1)
50.80% held by institutions, strong professional interest
Supporting Valuation Data
ProQR Therapeutics BV (PRQR) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 10.0x annual revenue
Micro-cap company with very limited liquidity and high volatility
Modest revenue growth at 6.10%
Fairly priced relative to book value
Supporting Valuation Data
ProQR Therapeutics BV (PRQR) Detailed Analysis Report
Overall Assessment
This company scores 22/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 8.0/10) while 7 fall into concern territory (avg 2.1/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (9.99), Price/Book (2.87) suggest expensive pricing. Growth concerns include Revenue Growth at 6.10%, which may limit upside. Profitability pressure is visible in Return on Equity at -61.20%, Operating Margin at -192.90%, Profit Margin at -258.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -61.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 6.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PRQR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PRQR's Price-to-Sales ratio of 9.99x trades at a deep discount to its historical average of 755.16x (3th percentile). The current valuation is 100% below its historical high of 9988.02x set in Nov 2014, and 28% above its historical low of 7.8x in Mar 2025. Over the past 12 months, the PS ratio has expanded from ~7.8x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for ProQR Therapeutics BV (PRQR) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
ProQR Therapeutics BV is in a turnaround phase, with management focused on restoring profitability. Revenue reached 16M with 6% growth year-over-year. The company is currently unprofitable, posting a -258.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.29 indicates a conservative balance sheet with 107M in cash.
Spending 60% of revenue (10M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -258.0% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -14M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact ProQR Therapeutics BV.
Bottom Line
ProQR Therapeutics BV is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About ProQR Therapeutics BV(PRQR)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders. The company is headquartered in Leiden, the Netherlands.